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Abstract: Background and Purpose- MRproANP (midregional proatrial natriuretic peptide) is known
to be independently associated with cardioembolic stroke cause and to improve risk stratification for
90-day mortality when measured within 24 to 72 hours after symptom onset in patients with acute
ischemic stroke. However, the optimal time point for assessment remains unclear. This study aimed to
evaluate prognostic utility of MRproANP at different time points during the first 5 days of hospitalization
in patients with acute ischemic stroke. Methods- Samples of MRproANP were collected on admission
(<72 hours after onset) and at multiple time points during the first 5 days of hospitalization in 348
consecutively enrolled patients with acute ischemic stroke. The prognostic value for 90-day mortality, 90-
day functional outcome, and the association with cardioembolic stroke cause was assessed regarding the
time of measurement, and change over time was modeled using generalized estimating equations. Results-
MRproANP levels modestly decease over the initial 5 days but remain highly predictive for cardioembolic
stroke cause (odds ratio, 9.75 [95% CI, 3.2-29]; 10.62 [95% CI, 3.4-33.3]; 10.8 [95% CI, 3.1-37.1]; 19.4
[95% CI, 5.49-68.7] on admission, day 1, 3 and 5) and 90-day mortality (odds ratio, 59.4 [95% CI, 7.4-
480.7]; 78.3 [95% CI, 7.9-772.6]; 14.5 [95% CI, 1.4-145]; 19.81 [95% CI, 2.7-143.4] on admission, day 1, 3,
and 5). Change over time does not significantly modify the prognostic value of MRproANP (P=0.65 and
P=0.56 for the interaction term in the multivariate model). Conclusions- Independent prognostic value of
MRproANP remains unaltered in the acute phase of stroke at least up to 5 days; repeated measurements
do not improve the prognostic value.
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Background and Purpose: Midregional proatrial natriuretic peptide (MRproANP) is 40 
known to be independently associated with cardioembolic (CE) stroke etiology and to 41 
improve risk stratification for 90-day mortality when measured within 24-72h after 42 
symptom onset in acute ischemic stroke (AIS) patients. However, the optimal time-43 
point for assessment remains unclear. This study aimed to evaluate prognostic utility 44 
of MRproANP at different time-points during the first 5 days of hospitalization in AIS 45 
patients.  46 
 47 
Methods: Samples of MRproANP were collected on admission (< 72h after onset) and 48 
at multiple time-points during the first 5 days of hospitalization in 348 consecutively 49 
enrolled AIS patients. The prognostic value for 90-day mortality, 90-day functional 50 
outcome and the association with CE stroke etiology was assessed regarding the time 51 
of measurement and change over time was modeled using generalized estimating 52 
equations (GEE).  53 
 54 
Results: MRproANP levels modestly decease over the initial 5 days but remain highly 55 
predictive for CE stroke etiology (OR: 9.75 [95% CI: 3.2–29]; 10.62 [3.4–33.3]; 10.8 56 
[3.1–37.1]; 19.4 [5.49–68.7] on admission, day 1, 3 and 5) and 90-day mortality (OR 57 
59.4 [7.4–480.7]; 78.3 [7.9–772.6]; 14.5 [1.4–145]; 19.81 [2.7–143.4] on admission, 58 
day 1, 3 and 5). Change over time does not significantly modify the prognostic value 59 
of MRproANP (p=0.65 and p=0.56 for the interaction term in the multivariate model). 60 
 61 
Conclusion: Independent prognostic value of MRproANP remains unaltered in the 62 
acute phase of stroke at least up to 5 days; repeated measurements do not improve 63 
the prognostic value. 64 
Introduction 1 
 2 
In patients with acute ischemic stroke (AIS) blood biomarkers have the potential to 3 
provide objective, reliable and timely information in addition to clinical assessments.   4 
Midregional proatrial natriuretic peptide (MRproANP) is the prohormone fragment of 5 
ANP, a vasoactive hormone synthesized in atrial cardiac tissue and secreted in 6 
response to stretching forces. It was shown to improve risk stratification for 90-day 7 
mortality and to be associated with cardioembolic (CE) stroke etiology when measured 8 
up to 72h after symptom onset, thus MRproANP may facilitate the selection of patients 9 
for prolonged cardiac monitoring or anticoagulation in the future1. However, little is 10 
known about the short-time dynamics of MRproANP in the acute setting of stroke, thus 11 
optimal time-point for the assessment remains unknown. The aim of this study was to 12 
characterize the time-course of MRproANP in AIS during the first 5 days and assess 13 
its prognostic value concerning CE stroke etiology, 90-day mortality and functional 14 
outcome at different time-points.  15 
 16 
Methods 17 
The data supporting the findings of this study are available from the corresponding 18 
author on reasonable request. The local Ethics Committee approved the study protocol 19 
and informed consent was obtained from all patients. A detailed methods section is 20 
available in the online-only supplement. 21 
Briefly, we analyzed data of a prospective cohort study. 348 participants with the 22 
diagnosis of AIS were included for longitudinal biomarker analysis. Patients that did 23 
not survive the first 5 days (n=11) were excluded (Figure I of the supplementary 24 
material). Baseline characteristics, comorbidities and neurological deficits were 25 
recorded on admission. Stroke etiology was determined after standardized diagnostic 26 
workup and patients were followed-up for 90 days. Blood samples were taken on 27 
admission, day 1, 3 and 5, respectively. We performed binary logistic regression 28 
analysis controlled for age and 2 to 3 main predictors to evaluate the association of 29 
MRproANP at different time-points with the predefined outcomes. To assess whether 30 
MRproANP remains a clinically relevant predictor we compared receiver operating 31 
characteristic (ROC) curves for models with and without MRproANP. Further, we used 32 
a generalized estimating equations (GEE) model  with an interaction-term for time of 33 
measurement to asses if there is a change in the prognostic value over time.  34 
 35 
Results 36 
Baseline characteristics of the full cohort (n=359) are summarized in Table I of the 37 
supplementary material. Median age was 75 years, 42% of participants where 38 
female, 12% deceased within the first 90-days, 42% had an unfavorable outcome. In 39 
36% of cases etiological workup revealed CE stroke etiology (detailed description is 40 
available in Table II of the supplemental material). Blood samples were available on 41 
admission, day one (87.9%), three (76.7%) and five (74.7%), respectively. Overall, 42 
MRproANP levels significantly differed between the first 5 days (p<0.001) with the 43 
highest values on admission. The 11 patients excluded from biomarker analysis due 44 
to lack of repeated measurements were significantly older (85 vs 75 years), had 45 
higher NIHSS (21 vs 5 points) and a higher rate of TACS (63% vs 8%) than the 46 
remaining cohort (Table III of the supplementary material).  47 
 48 
On all time-points MRproANP levels were significantly higher in CE stroke patients, 49 
patients with unfavorable outcome and patients who died within 90 days (Figure 1).  50 
 51 
MRproANP and cardioembolic stroke: Logistic regression analysis revealed that 52 
the association of MRproANP with cardioembolic stroke etiology remained stable 53 
over the period of 5 days independent of age, history of heart failure and AF (OR: 54 
9.75 [95% CI: 3.2–29]; 10.62 [95% CI: 3.4–33.3]; 10.8 [95% CI: 3.1–37.1]; 19.4 [95% 55 
CI: 5.49–68.7] on admission, day 1, day 3 and day 5 respectively).  56 
ROC analysis of the prediction model for CE stroke etiology showed that MRproANP 57 
significantly improves the prediction model at every time-point (p< 0.001) (Figure II 58 
and Table IV of the supplementary material). To further evaluate the association of 59 
MRproANP trajectories and CE stroke etiology, we used GEE to model the change of 60 
MRproANP. Interaction terms of MRproANP and time of measurement revealed no 61 
significant difference in the prognostic value (p=0.65 in the final model).  62 
 63 
MRproANP and functional outcome: In logistic regression MRproANP was 64 
associated with unfavorable outcome at every time-point (OR: 7.89 [95% CI: 3.62–65 
17.18]; 12.54 [95% CI: 5.1–30.3]; 10.4 [95% CI: 4–26.9]; OR 6.54 [95% CI: 2.7–15.8] 66 
on admission, day 1, day 3 and day 5) but did not remain an independent predictor 67 
after adjusting for main predictors (CCI, NIHSS and TACS). In the GEE model, 68 
interaction analysis revealed no significant change in the prognostic ability over time 69 
(p=0.56 in the final model).  70 
 71 
MRproANP and mortality: After adjusting for age, congestive heart failure and the 72 
two main predictors for mortality (TACS and NIHSS on admission), MRproANP 73 
remained a strong independent predictor for 90 day mortality (OR 59.4 [95% CI: 7.4–74 
480.7]; 78.3 [95% CI: 7.9–772.6]; 14.5 [95% CI: 1.4–145]; 19.81  [95% CI: 2.7–143.4] 75 
on admission, day 1, day 3 and day 5) respectively. MRproANP significantly 76 
improved the model at every time-point (p<0.001 on admission and day 1, p<0.05 on 77 
days 3, p<0.01 on day 5) (Figure II and Table IV of the supplementary material). GEE 78 
model again showed no significant change in the prognostic ability over time (p=0.56 79 
in the final model).  80 
 81 
Additional interaction analysis for Body Mass Index (BMI) which is known to influence 82 
MRproANP levels did not show any significant interaction (p=0.21; p=0.13; p= 0.26 83 
for CE stroke, functional outcome and mortality).   84 
 85 
Discussion  86 
It has previously been shown that MRproANP is associated with the predefined 87 
outcomes when single-sampled in AIS patients1, 2, however the short-time release 88 
kinetics of MRproANP in the immediate aftermath of AIS have not been described. 89 
Yet, it has been demonstrated that MRproANP levels can change rapid enough to be 90 
followed in the acute setting of stroke3 and that repeated measurements of 91 
MRproANP can improve the diagnostic and prognostic utility in other disease 92 
settings4, 5.  93 
In contrast, our data shows that the prognostic value of MRproANP for the reported 94 
outcomes remains unaltered in the acute phase of stroke. While the crude odds 95 
differed between time-points, stable AUCs suggesting that there is no preferred time-96 
point for the assessment. In addition, using GEE modeling, MRproANP change over 97 
time revealed no significant difference in the prognostic utility. Thus, we concluded 98 
that there is no benefit in repeated measurements and that early as well as later 99 
measures will provide similar prognostic information. However, the underlying 100 
pathophysiological mechanisms which are responsible for the observed release 101 
kinetiks are not fully understood yet. Especially, it remains unclear to what extend 102 
MRproANP levels reflect underlying cardiac disease already present before the event 103 
or a disturbance in neuro-cardiac control as a reaction to the event.  It has been 104 
shown that stroke location correlates with post-stoke biomarker changes and 105 
occurrence of post stroke arrhythmias6, 7 supporting the hypothesis of an autonomic 106 
connection between the brain and heart. On the other hand MRproANP was shown 107 
to independently predict ischemic stroke and AF when measured in stroke free 108 
individuals8, 9 suggesting that MRproANP levels also reflect preexisting cardiac 109 
disease. Further studies are needed to elucidate the complex interplay between 110 
MRproANP levels, cardiac function, stroke-risk and mortality. Our study has several 111 
limitations. First, it is a single-center study, thus it needs to be externally validated. 112 
Second, due to the longitudinal design there has been a number of missing 113 
MRproANP values due to missed blood draws, transfer to referring primary care 114 
hospitals and rehabilitation centers or early discharges. To account for this fact we 115 
applied GEE models which are robust to missing data. Despite these limitations our 116 




The prognostic value of MRproANP for mortality, 90-day functional outcome and 121 
cardioembolic stroke etiology remains stable over the short period of 5 days in AIS 122 
patients. Analysis of the time-course of MRproANP does not support a preferred 123 
time-point for assessment or additional value of repeated measurements. 124 
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Figure 1 – Boxplot of MRproANP levels at different time-points in regard to outcome variables 
 
A Association of MRproANP with cardioembolic (CE) stroke etiology. B Association of MRproANP with 






Study design: To assess the short-time trajectories of MRproANP we analyzed data of a 
prospective cohort study as described in detail elsewhere1. Briefly, a total of 605 consecutive 
patients with a suspected cerebrovascular event were initially enrolled within 72h from symptom 
onset. 359 patients had a diagnosis of AIS defined according to the World Health Organization 
criteria and completed 90 day follow up. For the longitudinal biomarker analysis, we included 348 
participants. Patients that did not survive the first 5 days after admission (n=11) had to be excluded 
since repeated measurements of MRproANP were not possible and missing values were not 
considered as missing at random. Baseline characteristics including demographic variables and 
comorbidities were recorded on admission by patient history and review of discharge letters. 
Relevant comorbidities were assessed by the Charlson comorbidity index (CCI) adjusted for stroke2. 
Hypertension was defined as blood pressure above 140/90 mmHg repeatedly or currently under  
medical treatment with antihypertensive agents. Dyslipidemia was defined as low density 
lipoprotein (LDL) levels above 2,6mmol/L or currently under medical treatment with lipid-lowering 
drugs. Active smoking status was defined as current smoking or stopped within the previous 2 
years. A positive family history was defined as a cardiovascular event (stroke or myocardial 
infarction) in a first grade relative aged ≤ 65 years. Congestive heart failure was defined as 
exertional or paroxysmal nocturnal dyspnea that has responded to treatment. Neurological deficits 
on admission were assessed by a stroke neurologist using the National Institute of Health Stroke 
Scale (NIHSS). Stroke etiology was determined according to the TOAST (trial of Org 10172 in Acute 
Stroke Treatment) classification at discharge. All patients underwent standardized diagnostic 
workup including brain computer-tomography (CT), magnet resonance imaging (MRI), or both; 
standard 12‐lead ECG; 24‐h-ECG; echocardiography; and neurosonographic examination. The 
clinical stroke syndrome was determined applying the criteria of the Oxfordshire Community 
Stroke Project 3. Mortality and functional outcome according to the modified Ranking Scale (mRS) 
was assessed via a structured telephone interview on day 90, blinded to MRproANP levels. A 
favorable outcome was defined as a mRS score of 0 to 2. The local Ethics Committee approved 
the study protocol (EKBB#157/06) and informed consent was obtained from all patients. 
Anonymized study data is available on reasonable request.  
 
Sample Processing: Blood samples were available on admission and on day 1, 3 and 5 
respectively. Blood was collected in EDTA containing plastic tubes, centrifuged locally at 3000g at 
4° C for 20 minutes and plasma was immediately aliquoted and frozen at -80°C. MRproANP was 
measured in a blinded batch analysis with a sandwich immunoassay (BRAHMS AG, Henningsdorf, 
Germany) as described in detail elsewhere 4. Three hundred twenty-eight patients (93.4%) had at 
last two separate measurements during the course of the study. 
 
Statistical Analysis: Discrete variables are summarized as counts (percentages) and continuous 
variables as medians (interquartile ranges [IQR]) in the baseline characteristics. For two group 
comparisons, Fisher's exact test and Mann–Whitney U test was used depending on the variable 
type. Common logarithmic transformation (base 10) was performed to transform to normality for 
skewed distributions (e.g. MRproANP levels). Skillings–Mack test for repeated measures with 
missing data was used to assess MRproANP changes over time in a non-parametric fashion. To 
evaluate the association of logMRproANP measured at different time-points with CE etiology, 90-
day functional outcome and 90-day mortality binary logistic regression analysis was performed. 
We controlled for age and 2 to 3 main predictors depending on the outcome variable to avoid 
overfitting (i.e. congestive of heart failure and atrial fibrillation (AF) for CE stroke etiology; NIHSS, 
Charlson Comorbidity Index (CCI) and total anterior circulation syndrome (TACS) for 90-day 
functional outcome; TACS, NIHSS and congestive heart failure for 90-day mortality). Receiver 
Operating Characteristic (ROC) curves and the area under the ROC curve (AUC) were calculated 
for the models with and without logMRproANP. The likelihood ratio test was used to compare 
nested vs the respective whole models (including logMRproANP) at each time-point, in order to 
assess whether MRproANP remains an independent and clinically relevant predictor during the 
observational period. Further, to account for within subject correlation and the unequal number 
of repeated measurements in the same individuals over time we used a generalized estimating 
equations (GEE) model with a probit link for the binary outcomes. Since GEE models are robust to 
errors in specification of the correlation structure 5 all models were fitted using an independent 
correlation structure. To asses if there is a change in the prognostic value over time, we included 
an interaction term for logMRproANP and the time of measurement. GEE models were performed 
with logMRproANP alone and with age and the two main predictors for each outcome as specified 
above. Because of the potential influence of body mass index (BMI) on MRproANP levels we 
performed additional interaction analysis for BMI and logMRproANP in bivariate and multivariate 
GEE models. P-values < 0.05 were considered statistically significant. Data analysis was performed 
using STATA version 15 (StataCorp LLC, College Station, Texas). 
 
  
Supplementary Figure I – Study flow chart  
 
 
Supplementary Figure II – Receiver operating characteristic curve for models in- and ex-
cluding logMRproANP levels according to outcome variables. 
 
 
A – ROC curves of the nested model 1 including age, congestive heart failure and known atrial fibrillation (AF) (red line) and model 2 
inlcuding age, congestive heart failure, AF and logMRproANP (blue line) with cardioembolic (CE) stroke etiology as the outcome 
variable. B – ROC curves of the nested model 1 including age, NIHSS, total anterior circulation syndrom (TACS) and congestive heart 
failure (red line) and model 2 inlcuding age, NIHSS, TACS, congestive heart failure and logMRproANP (blue line) with 90-day 
mortality as the outcome variable. 
 
Supplementary Table I – Baseline Characteristics  
  Stroke Etiology Functional Outcome Mortality at 90 days 
 All CE stroke Non CE stroke p Value mRS 0-2 mRS 3-6 p Value Alive Dead p Value 
n (%) 359 (100) 131 (36) 228 (64) - 208 (58) 151 (42) - 315 (88) 44 (12) - 
Demographics           
  Age*, median (IQR) 75 (63-83) 76 (65-82) 75 (62-83) 0.43 71 (59-80) 80 (71-86) < 0.001 74 (61-82) 83 (78-87) < 0.001 
  Female sex, n (%) 149 (42) 60 (46) 89 (39) 0.22 75 (50) 74 (36) < 0.01 128 (40) 21(48) 0.42 
Medical history           
  Arterial hypertension, n (%) 275 (77) 106 (81) 169 (74) 0.16 152 (73) 123 (81) 0.08 238 (76) 37 (84) 0.26 
  Smoking status, n (%) 124 (35) 42 (32) 82 (36) 0.49 79 (38) 45 (30) 0.12 113 (36) 11 (25) 0.18 
  Diabetes mellitus, n (%) 71(20) 24 (18) 47 (21) 0.68 39 (19) 32 (21) 0.59 62 (20) 9 (20) 0.84 
  Family history of vascular events, n (%) 106 (30) 37 (28) 69 (30) 0.72 67 (32) 39 (26) 0.2 94 (30) 12 (27) 0.86 
  Congestive heart failure, n (%) 54 (15) 31 (24) 23 (10) < 0.001 21 (10) 33 (21) < 0.01 42 (13) 12 (27) 0.02 
  Dyslipidemia, n (%) 93 (26) 31 (24) 62 (27) 0.53 58 (28) 35 (23) 0.33 82 (26) 11 (25) 1 
  Coronyry artery disease, n (%) 91 (25) 38 (29) 53 (23) 0.26 48 (23) 43 (29) 0.27 74 (24) 17 (39) 0.04 
  Prior Stroke, n (%) 88 (25) 32 (24) 56 (25) 0.54 48 (23) 40 (26) 0.45 80 (25) 8 (18) 0.35 
  Atrial fibrillation, n (%) 75 (21) 62 (47) 13 (6) < 0.001 41 (27) 34 (16) 0.02 18 (41) 57 (18) 0.001 
  Charlson Index
&
, median (IQR) 1 (0-2) 1 (0-2) 1 (0-2) 0.1 0 (0-2) 1 (0-2) < 0.001 1 (0-2) 1 (0-2) 0.09 
  BMI 
£
, median (IQR) 25.4 (23-28) 24.8 (22-28) 25.5 (23-8) 0.28 24.5 (21-27) 25.7 (24-28) <0.05 25.5 (23-28) 23.1 (21-26) < 0.001 
Stroke Syndrome, n (%)           
  PACS 162 (45) 72 (55) 90 (39) < 0.01 92 (44) 70 (46) 0.74  144 (46) 18 (41) 0.62 
  TACS 41 (11) 19 (15) 22 (10) 0.17 11 (5) 30 (20) < 0.001 25 (8) 16 (36) < 0.001 
  LACS 74 (21) 16 (12) 58 (25) 0.003 47 (23) 27 (18) 0.29 70 (22) 4 (9) 0.05 
  POCS 82 (23) 24 (18) 58 (25) 0.15 58 (28) 24 (16) 0.008 76 (24) 6 (14) 0.13 
Stroke severity           
  NIHSS, median  (IQR) 5 (2-10) 6 (3-13) 5 (2-9) 0.03 4 (2-6) 8 (4-17) <0.001 4 (2-8) 17.5 (8.5-25) <0.001 
Laboratory, median (IQR)           
  Creatinine (umol/L)
¶
 76 (63-90) 77 (64-91) 75 (63-88) 0.52 76 (64-89) 76 (63-91) 0.92 75 (62-88) 81 (64-99) 0.19 
  MRproANP Admission
§
 (pmol/L) 143 (83-238) 206 (120-326) 125 (72-207) < 0.001 122 (73-189) 213 (119-333) < 0.001 132 (78-217) 345 (228-465) < 0.001 
  MRproANP Day 1
§
 (pmol/L) 131 (84-228) 219 (116-311) 115 (72-172) < 0.001 112 (70-169) 212 (116-291) < 0.001 120 (79-214) 288 (214-415) < 0.001 
  MRproANP on Day 3
§
 (pmol/L) 135 (81 – 213) 204 (113-270) 107 (75-169) < 0.001 114 (70-172) 188 (96-264) < 0.001 124 (78-196) 259 (215-410) < 0.001 
  MRproANP on Day 5
§
 (pmol/L) 113 (77 – 204) 184 (95-283) 98 (67-1255) < 0.001 100 (65-176) 155 (83-256) < 0.001 107 (74-187) 300 (174-433) < 0.001 
 
Values are median (IQR) or counts (%) ( * age was missing in 0,3%; § MRproANP values were missing in 6,4% on admission, 13% on day 1, 26% on day 3 and 27% on day 5); ¶ creatinine values were missing 
on 2,5% on admission; 
& 
charlson index values were missing in 0,8% on admission;
 £ 
BMI was missing in 12% on admission).  P-Values were assessed using the Fisher's exact test and Mann–Whitney U test 
depending on the variable type. IQR = interquartile range; LACS = lacunar syndrome; NIHSS = National Institutes of Health Stroke Scale; PACS = partial anterior circulation syndrome; POCS = posterior 
circulation syndrome; TACS = total anterior circulation syndrome; BMI = body mass index 
 
Supplementary Table II – Observed sources of cardiac embolism in TOAST 2 classified strokes 
Cardioembolic Stroke, n (%) 131 
   Known atrial fibrillation 62 (47) 
   Newly diagnosed atrial fibrillation during hospitalisation 23 (18) 
   Patent foramen ovale and / or septal aneurysm 20 (15.5) 
   Congestive heart failure 8 (6) 
   Atrial flutter 2 (1.5) 
   Other * 16 (12) 
 
 * includes high-risk sources (mechanical prosthetic valve, left atrial / ventricular thrombus, sick sinus syndrome, recent myocardial 
infarction, dilatated cardiomyopathy, atrial myxoma, endocarditis) and medium-risk sources (mitral valve prolaps, mitral anulus 
calcification, mitral stenosis, bioprosthetic cardiac valve, local hypokinetic segment) of cardioembolism.  
 
Supplementary Table III – Comparison of baseline characteristics between analysed subset 
and excluded patients 
 Full cohort Analysed subset Excluded Patients p-value 
n (%) 359 (100) 348 (97) 11 (3) - 
Demographics     
  Age, median (IQR)  75 (63-83) 75 (63 – 82) 85 (81-90) < 0.001 
  Female sex, n (%) 149 (42) 144 (41) 5 (45) 0.77 
  Medical history     
  Arterial hypertension, n (%) 275 (77) 165 (76) 10 (91) 0.47 
  Smoking status, n (%) 124 (35) 122 (35) 2 (18) 0.34 
  Diabetes mellitus, n (%)  71 (20) 70 (20) 1 (9) 0.7 
  Family history of vascular events, n (%) 106 (30) 106 (30) 3 (27) 1 
  Congestive heart failure, n (%)   54 (15) 50 (14) 4 (36) 0.07 
  Dyslipidemia, n (%) 93 (26) 92 (26) 1 (9) 0.3 
  Coronary artery disease, n (%) 91 (25) 87 (25) 4 (36) 0.48 
  Prior Stroke, n (%) 88 (25) 85 (24) 3 (27) 0.74 
  Charlson Index, median (IQR)  1 (0-2) 1 (0-2) 1 (1-2) 0.36 
  BMI, median (IQR) 25.4 (23-27.8) 22 (21.1-26.8) 25.4 (23-27.8) 0.1 
Stroke Syndrome, n (%)     
  PACS 162 (45) 160 (46) 2 (18) 0.12 
  TACS 41 (11) 34 (10) 7 (64) < 0.001 
  LACS 74 (21) 73 (21) 1 (9) 0.47 
  POCS 82 (23) 81 (23) 1 (9) 0.47 
Stroke severity     
  NIHSS, median (IQR) 5 (2-10) 5 (2-10) 21 (11-26) < 0.001 
Laboratory      
  Creatinine (µmol/L), median (IQR) 76 (63-89.5) 76 (63-89) 89 (68-133) 0.1 
 
Values are median (IQR) or counts (%). P-values were assessed using the Fisher's exact test and Mann–Whitney U test depending on 
the variable type. IQR = interquartile range; NIHSS = National Institutes of Health Stroke Scale; BMI = body mass index; LACS = 





Supplementary Table Table IV – Overview of Areas Under the Receiver Operating 
Characteristic curves.  
Prediction Model AUC (95% CI)  
 logMRproANP alone Model 1 Model 2 P value 
CE Stroke Etiology     
   Admission  0.70 (0.63-0.75) 0,76 (0.71-0.82) 0,82 (0.77-0.87) < 0.001 
   Day 1  0.72 (0.66-0.78) 0,77 (0.71-0.83) 0,82 (0.78-0.88) < 0.001 
   Day 3 0.71 (0.64-0.77) 0,76 (0.7-0.82) 0,81 (0.75-0.87) < 0.001 
   Day 5  0.70 (0.63-0.77) 0,76 (0.7-0.82) 0,83 (0.77-0.88) < 0.001 
90-day Functional Outcome      
   Admission 0.68 (0.62-0.74) 0.82 (0.78-0.88) 0.83 (0.78-0.87) 0.70 
   Day 1 0.70 (0.64-0.76) 0.84 (0.79-0.89) 0.84 (0.80-0.89) 0.17 
   Day 3 0.68 (0.61-0.75) 0.80 (0.75-0.86) 0.81 (0.75-0.86) 0.14 
   Day 5  0.66 (0.59-0.73) 0.81 (0.75-0.86) 0.81 (0.75-0.86) 0.91 
90-day Mortality     
   Admission  0.85 (0.80-0.90) 0.89 (0.84-0.94) 0.92 (0.88-0.96) < 0.001 
   Day 1 0.83 (0.77-0.89) 0.90 (0.85-0.94) 0.92 (0.88-0.96) < 0.001 
   Day 3 0.82 (0.73-0.91) 0.90 (0.84-0.95) 0.91 (0.85-0.96) < 0.05 
   Day 5 0.83 (0.74-0.92) 0.88 (0.83-0.93) 0.90 (0.85-0.96) < 0.01 
 
Area under the receiver operating characteristic curve (AUC) of logMRproANP alone and of different prognostic models. Model 1 
includes age and 2 to 3 main predictors (congestive heart failure and atrial fibrillation (AF) for cardioembolic stroke; National Institute 
of Health Stroke Scale (NIHSS), total anterior circulation syndrom (TACS) and Charlson Comorbidity Index (CCI) for functional 
outcome; NIHSS, TACS and congestive heart failure for mortality). Model 2 includes age and the same main predictors plus 
logMRproANP levels on different time-points. P values indicate significance of the difference between Model 1 and Model 2 
(likelihood ratio test). 
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